NICE issues final draft guidance for tixagevimab-cilgavimab (Evusheld®) for prevention of COVID-19

Final draft guidance published for tixagevimab-cilgavimab (Evusheld®) for prevention of COVID-19

Following consultation, final draft guidance has been published by the National Institute for Health and Care Excellence (NICE) for tixagevimab-cilgavimab (Evusheld®) for prevention of COVID-19. There is no difference to the decision, compared to the draft guidance decision published previously.

NICE and the Scottish Medicines Consortium (SMC, as part of Healthcare Improvement Scotland) agreed to maintain the collaboration that started through the Research to Access Pathway for Investigational Drugs for COVID-19 (RAPID C-19) by collaborating on the NICE STA. SMC has had direct input into the decision-making committee that produced the draft guidance. The final published advice will have the same status for health board consideration as other SMC advice on new medicines.

NICE and the SMC will continue to work together on any updates to this STA after publication.

A new NICE rapid surveillance and evaluation process for COVID-19 treatments is being developed so that they can be made available more quickly if they show promise against new variants.

You can read more about the final draft guidance here:  Final draft guidance | Project documents | Tixagevimab plus cilgavimab for preventing COVID-19 [ID6136] | Guidance | NICE